ILC Dover | AI Transformation Index

ILC Dover is a structurally exceptional durability story: a physical manufacturer of safety-critical, specification-driven products in FDA-regulated biopha...

ILC DoverAerospace & Defense (Manufacturing - Miscellaneous)New Mountain Capital

Overview

ILC Dover designs and manufactures high-performance engineered flexible containment and protective solutions — including single-use bioprocessing bags, pharmaceutical containment systems, spacesuits, aerostats, and protective respiratory equipment — for biopharmaceutical, pharmaceutical, medical device, and aerospace/defense customers, generating revenue through engineered product sales and customized solutions in heavily regulated, specification-driven markets.

Executive Summary

ILC Dover is a structurally exceptional durability story: a physical manufacturer of safety-critical, specification-driven products in FDA-regulated biopharma and NASA-qualified aerospace markets, where AI-native entry is practically foreclosed by multi-year qualification cycles, materials science barriers, and capex requirements. The business earns its moat through physical execution and regulatory positioning that AI cannot replicate or bypass. The tradeoff is that AI opportunity is correspondingly modest — the business has limited cognitive labor pools to compress, physical constraints that AI cannot remove, and a production function that benefits from AI at the engineering and documentation margins rather than at its core. For a PE investor, this is a high-confidence durability asset with limited AI upside risk in either direction: AI neither threatens it meaningfully nor transforms it dramatically.

Durability

How resilient is this business against AI disruption?

FactorValue

Market Substitutability

9

Profit Pool Migration

8

Barrier to Entry

9

Disintermediation Exposure

9

Switching Costs

8
Total86.0
×

Opportunity

How big a deal is AI for this business?

FactorValue

AI Applicability

4

Improvement Magnitude

4

Transformation Upside

3

Domain Intelligence Amplification

5
Total40.0

58.7

Ciridae AI Score

Durability Rationale

ILC Dover's durability is among the strongest in any portfolio — it manufactures safety-critical, physically delivered, regulated products across two of the most barrier-protected end markets in the economy (biopharma manufacturing and aerospace/defense). The core customer outcome is irreducibly physical: a validated containment bag, a certified spacesuit, a qualified aerostat cannot be replaced by software or AI inference. Structural protection layers are multiple and mutually reinforcing — FDA GMP validation cycles, NASA qualification programs, long-dated embedded supplier relationships, and significant materials science IP combine to make AI-native entry essentially impossible in any foreseeable timeframe. The company's position is not that of an intermediary at risk of disintermediation; it is a system-of-record physical manufacturer whose switching costs are measured in years and regulatory filings, not software migration costs.

Opportunity Rationale

AI's transformative potential for ILC Dover is genuinely limited — not because AI is irrelevant, but because the business is overwhelmingly physical in its value creation. The engineering and R&D workflows can benefit from AI-assisted simulation, faster design iteration, and automated regulatory documentation, and ILC Dover's deep proprietary knowledge in flexible materials is a real domain intelligence asset. However, the production function cannot be fundamentally restructured by AI: manufacturing engineered fabric structures, passing quality inspections, and navigating regulatory validation are physical, capital, and process-intensive activities that AI augments at the margin rather than transforms. There is no large cognitive workforce to compress, no throughput multiplication available through AI, and no fundamentally new business model AI unlocks — the opportunity is real but incremental.

Key Risks

The durability assessment could be wrong if biopharma customers accelerate in-house development of single-use bioprocessing solutions, leveraging AI-assisted materials design tools to qualify alternative suppliers faster than historical norms — compressing switching costs through AI-accelerated validation.

The opportunity assessment could be wrong if AI-assisted generative design and materials simulation tools prove transformative for engineered flexible products R&D, enabling ILC Dover to dramatically shorten new product development cycles and expand addressable markets in ways current AI capability benchmarks understate.

Company Overview

HeadquartersFrederica, Delaware, United States
Products / Services
Engineered products using high-performance materials, Single-use powder and liquid handling systems, Biopharmaceutical and pharmaceutical manufacturing solutions, Medical device solutions, Aerospace products including spacesuits and aerostats, Flexible flood barriers, Protective respiratory equipment (e.g., PAPR hoods)
Deal Partners

PE / Ownership History

EventDetails
Sold to Ingersoll Rand
March 2024
Sold to Ingersoll Rand for approximately $2.3 billion in cash plus an earnout tied to 2024 operating results. The deal expanded Ingersoll Rand's life sciences presence and included ILC Dover's operations and product portfolio. Corey Walker continued as CEO through the sale to Ingersoll Rand.
Acquired by New Mountain Capital
February 2020
Financial details of the acquisition were not publicly disclosed. ILC Dover CEO during this period was Fran DiNuzzo initially, and later Corey Walker, who remained invested and led the company through growth phases.

Executives

NameBackground
Corey Walker
President and Chief Executive Officer (CEO)
Executive Vice President of the Americas and global Biomaterials and Electronic Materials businesses at Avantor (2016-2020). Other leadership roles held at DCP Midstream, Halliburton Energy Services, Dow Chemical, and Dell Technology. MBA from Harvard Business School.
Patrick Weinberg
Chief Financial Officer (CFO)
Executive positions at Royal DSM and Addivant in Europe and the US. Bachelor's degree in Economics, Master's degree in Accounting, and an MBA from Tilburg University in the Netherlands.
Scott Watson
Chief Operating Officer (COO)
Detailed professional background not fully available in the sources but listed as COO in multiple company profiles.
Kelly Lawry
Chief Human Resources Officer
Not available
Devashish Ohri
President, Asia
Not available
Tony Gonzalez
President, Flexan
Not available
Juergen Pongratz
President, Biotherapeutics and Pharmaceuticals
Not available
Rob Reed
President, Space & Engineered Solutions
Not available
Ian Sklar
Vice President of Quality and Regulatory Compliance
Not available
Brandon LaMar
Vice President of Corporate Development
Not available
Abby Holaschutz
Vice President, Transformation and Business Optimization
Not available
Fran DiNuzzo
Board of Directors (former CEO and President)
Not available